First FDA approved subcutaneous implantable defibrillator available for patients

Sudden cardiac arrest (SCA) is a condition in which the heart suddenly stops pumping blood. When this occurs, blood stops flowing to the brain and other major organs. Recent estimates show that approximately 850,000 people in the United States are at risk of SCA, and most of the people who have SCA, die from it. But, rapid treatment of SCA by using an implantable defibrillator can be lifesaving.

On September 28th, 2012, the FDA approved the world's first totally subcutaneous implantable defibrillator (S-ICD). Northwestern's Bluhm Cardiovascular Institute is one of the first 20 institutions in the country to have access to this technology. Since FDA approval, the Bluhm Cardiovascular Institute is one of the first ten places to implant in the U.S.

"The S-ICD system provides physicians with a new treatment option for patients who are at risk of ," said Bradley Knight, MD, electrophysiologist and medical director of the Center for . "The system sits entirely below the skin without requiring the need for placing wires in the heart, which leaves the heart and blood vessels untouched."

The Boston Scientific S-ICD® System has two main components. One is called the pulse generator, which powers the system, monitors and delivers a shock if needed. The other main component is the electrode. This enables the device to sense the heart rhythm and deliver shocks when necessary. Both are implanted just under the skin, providing protection without touching the heart and reliable without transvenous wires.

"Patients who previously could not undergo the implantation of a transvenous defibrillator, now have a device option to protect them from deadly arrhythmias," said Dr. Knight.

The S-ICD system is commercially available in many countries in Europe as well as New Zealand. More than 1,400 devices have been implanted in patients around the world.

add to favorites email to friend print save as pdf

Related Stories

US approves less-invasive heart defibrillator

Sep 29, 2012

(AP)—The U.S. Food and Drug Administration says it has approved a first-of-a-kind heart-zapping implant from Boston Scientific that that does not directly touch the heart.

Recommended for you

Cerebrovascular reserve-based strategy is cost-effective

Jan 29, 2015

(HealthDay)—A decision rule based on assessment of cerebrovascular reserve (CVR) seems to be cost-effective for prevention of stroke in asymptomatic patients with carotid artery stenosis, according to a ...

New hypertension guidelines could save lives and money

Jan 28, 2015

Full implementation of new hypertension guidelines could prevent 56,000 cardiovascular disease events (mostly heart attacks and strokes) and 13,000 deaths each year, without increasing overall health care costs, an analysis ...

Manchester United's rising stars revolutionize heart health

Jan 28, 2015

A unique research project to identify the effects of exercise on young hearts has been announced today [Wednesday 28 January 2015]. Manchester United's Academy players are being put through their paces having their hearts ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.